Search
Silexion Therapeutics Corp
SLXNAdd to Watchlist
0.436USD
+0.056+14.74%
Close 09-18 16:00（ET）
519.13KMarket Cap
LossP/E TTM
After-hours 19:41 (ET)0.392USD-0.048-10.91%
After-hours 19:41 (ET)More Details of Silexion Therapeutics Corp Company
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Silexion Therapeutics Corp Profile
Ticker SymbolSLXN
Company nameSilexion Therapeutics Corp
IPO dateFeb 17, 2021
CEOHadar (Ilan)
Number of employees11
Security typeOrdinary Share
Fiscal year-endFeb 17
Address12 Abba Hillel Road
CityRAMAT GAN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code5250606
Phone97286286005
Website
Ticker SymbolSLXN
IPO dateFeb 17, 2021
CEOHadar (Ilan)
Company Executives of Silexion Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Ilan Hadar
Mr. Ilan Hadar
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
16.55K
--
Mr. Ilan Hadar
Mr. Ilan Hadar
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
16.55K
--
Dr. Mitchell Shirvan, Ph.D.
Dr. Mitchell Shirvan, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
8.06K
-9.10%
Dr. Mitchell Shirvan, Ph.D.
Dr. Mitchell Shirvan, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
8.06K
-9.10%
Ms. Ruth Alon
Ms. Ruth Alon
Independent Director
Independent Director
1.03K
-0.10%
Ms. Ruth Alon
Ms. Ruth Alon
Independent Director
Independent Director
1.03K
-0.10%
Mr. Dror J. Abramov
Mr. Dror J. Abramov
Independent Director
Independent Director
--
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Prof. Shlomo Noy
Prof. Shlomo Noy
Independent Director
Independent Director
--
--
Ms. Mirit Horenshtein Hadar, CPA
Ms. Mirit Horenshtein Hadar, CPA
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ilan Hadar
Mr. Ilan Hadar
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
16.55K
--
Mr. Ilan Hadar
Mr. Ilan Hadar
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
16.55K
--
Dr. Mitchell Shirvan, Ph.D.
Dr. Mitchell Shirvan, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
8.06K
-9.10%
Dr. Mitchell Shirvan, Ph.D.
Dr. Mitchell Shirvan, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
8.06K
-9.10%
Ms. Ruth Alon
Ms. Ruth Alon
Independent Director
Independent Director
1.03K
-0.10%
Ms. Ruth Alon
Ms. Ruth Alon
Independent Director
Independent Director
1.03K
-0.10%
FAQs
Who are the top five shareholders of Silexion Therapeutics Corp?
The top five shareholders of Silexion Therapeutics Corp are: Mr. Ilan Hadar
How many institutions hold shares of Silexion Therapeutics Corp (SLXN)?
As of 2026Q1, 26 institutions hold shares of Silexion Therapeutics Corp, with a combined market value of approximately 170.10K, accounting for 4.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 116853.00.